Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIR-X56
- Development stage
- Preclinical
- Lead developer
- Sironax
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SIR-X56 is a novel, orally bioavailable small-molecule agonist of nicotinamide phosphoribosyltransferase (NAMPT), a rate-limiting enzyme in the nicotinamide adenine dinucleotide (NAD+) salvage pathway. By activating NAMPT, SIR-X56 increases intracellular NAD+ levels, which are essential for energy metabolism, redox homeostasis, and mitochondrial function. Preclinical studies have demonstrated that SIR-X56 restores muscle NAD+ levels and improves motor function in models of Duchenne muscular dystrophy (DMD) and aging, while also reducing cardiac injury and extending lifespan in models of Friedreich ataxia.
02
Targets
Beyond the preview
Go deeper on SIR-X56.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIR-X56.